Replies to post #1644 on Stem Cell Innovations (fka SCLL)

[THE GREEN EAGLE]

see post 1568

[locksflooring]

Last PR FDA's Hydroxycut Recall Highlights the Need for Stem Cell Innovations' ACTIVTox Human Liver Testing
Date : 05/21/2009 @ 8:00AM
Source : PR Newswire
Stock : (SCLL)
Quote : 0.0016 0.0 (0.00%) @ 8:18AM


FDA's Hydroxycut Recall Highlights the Need for Stem Cell Innovations' ACTIVTox Human Liver Testing





HOUSTON, May 21 /PRNewswire-FirstCall/ --

Stem Cell Innovations' (Pink Sheets: SCLL) ACTIVTox(R) human liver toxicity tests are the only products on the market using a standardized human liver cell line to identify potential toxicities associated with nutraceuticals and dietary supplements. This system is available now and can be used to help prevent future liver-related damage and death

"The use of our ACTIVTox testing system could help prevent recalls associated with liver toxicity," said James H. Kelly, PhD, CEO of Stem Cell Innovations, Inc. "ACTIVTox allows manufacturers to evaluate potential liver issues before release. This can be particularly important in the use of botanical extracts where both growing conditions and the extraction procedure can have dramatic effects on the composition of the final product."

ACTIVTox is designed to identify human liver toxicities associated with drugs, nutraceuticals and food supplements. "Consumers often have the impression that plant-based products are totally benign where, in fact, many of the most potent chemicals ever identified are plant products," said Kelly. "Particularly with the complex manufacturing challenges associated with the use of crude plant extracts, cell-based testing can give an extra measure of comfort to both the consumer and the producer. Considering the cost of developing, manufacturing and marketing new products, ACTIVTox testing protects your investment."

About Stem Cell Innovations, Inc

SCLL is a cell biology company based in Houston, TX. The Company's ACTIVTox system is a human liver based model for high throughput toxicity testing. Stem Cell Innovations proprietary, human pluripotent stem cells, known as PluriCells, have the potential to aid in drug discovery, toxicology, and cell therapy

Additional information is available at http://www.stemcellinnovations.com/ and at http://www.activtox.com/

ACTIVTox and PluriCells are Trademarks of Stem Cell Innovations, Inc


Forward Looking Statement

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Forward-looking statements are not statements of historical facts, but rather reflect our current expectations concerning future events and results. We use words such as "expects", "intends", "believes", "may", "will" and "anticipates" to indicate forward-looking statements. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including, but not limited to, those risks and uncertainties detailed in the Company's periodic reports filed with the Securities and Exchange Commission. We caution that these risk factors may not be exhaustive. We operate in a continually changing business environment, and new risk factors emerge from time to time. We cannot predict these new risk factors, nor can we assess the effect, if any, of the new risk factors on our business or the extent to which any factor or combination of factors may cause actual results to differ from those expressed or implied by these forward-looking statements

If any one or more of these expectations and assumptions proves incorrect, actual results will likely differ materially from those contemplated by the forward-looking statements. Even if all of the foregoing assumptions and expectations prove correct, actual results may still differ materially from those expressed in the forward-looking statements as a result of factors we may not anticipate or that may be beyond our control. While we cannot assess the future impact that any of these differences could have on our business, financial condition, results of operations and cash flows or the market price of shares of our common stock, the difference could be significant. We do not undertake to update any forward-looking statements made by us, whether as a result of new information, future events or otherwise. You are cautioned.

DATASOURCE: Stem Cell Innovations, Inc


CONTACT: James H. Kelly, [phone], for Stem Cell Innovations,

Inc


Web Site: http://www.stemcellinnovations.com/

http://www.activtox.com/



Bookmark With :

[locksflooring]

Click here for historical news »


Date Time Source Headline Symbol Company
07/02/2009 3:50PM EDGAR - Proxy Statement (definitive) (DEF 14A) USOTC:SCLL -
06/05/2009 11:26AM EDGAR - Proxy Statement - Notice of Shareholders Meeting (preliminary) (PRE 14A) USOTC:SCLL -
06/04/2009 2:09PM Form (8-K) - Current report filing USOTC:SCLL -
05/21/2009 8:00AM PRNUS FDA's Hydroxycut Recall Highlights the Need for Stem Cell Innovations' ACTIVTox Human Liver Testing USOTC:SCLL
02/24/2009 8:00AM PRNUS Stem Cell Innovations' C3A Human Liver Cell Line is Capable of Producing Biosimilar Serum Proteins for Follow-On Biologics USOTC:SCLL
02/05/2009 6:00AM PRNUS Stem Cell Innovations' PluriCells(TM) to Form the Basis of a Liver Assist Device to Support Patients Waiting for Transplant. USOTC:SCLL
01/23/2009 6:00AM PRNUS Stem Cell Innovations, Inc., Files New Patent Application Regarding Pluripotent Stem Cell Production USOTC:SCLL

[locksflooring]

1 Year HIGH still .10 http://money.cnn.com/quote/quote.html?symb=SCLL&time=1yr